<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526474</url>
  </required_header>
  <id_info>
    <org_study_id>P04737</org_study_id>
    <secondary_id>TRA 2°P - TIMI 50</secondary_id>
    <secondary_id>2006-002942-12</secondary_id>
    <secondary_id>MK-5348-015</secondary_id>
    <nct_id>NCT00526474</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Thrombolysis in Myocardial Infarction Study (TIMI) Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to determine whether vorapaxar, when added to the existing standard of
      care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants
      with a known history of atherosclerosis, will yield additional benefit over the existing
      standard of care without vorapaxar in preventing heart attack and stroke.

      The study is also designed to assess risk of bleeding with vorapaxar added to the standard of
      care versus the standard of care alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2007</start_date>
  <completion_date type="Actual">December 1, 2011</completion_date>
  <primary_completion_date type="Actual">December 1, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, or Urgent Coronary Revascularization (UCR) Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A Clinical Endpoints Committee (CEC) reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 3 years from randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, or Stroke Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, or stroke. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, or stroke within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Met Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) Moderate or Severe Bleeding Criteria Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Adverse events were categorized as &quot;bleeding events&quot; if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the GUSTO cooperative group criteria as follows: Mild , Moderate or Severe and the grading was adjudicated by the CEC. The Kaplan-Meier estimate reports the percentage of participants who experienced GUSTO moderate or severe bleeding within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Clinically Significant Bleeding Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Adverse events were categorized as &quot;bleeding events&quot; if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria as major, minor or other. &quot;Clinically Significant Bleeding&quot; was defined as the composite of TIMI Major bleeding, TIMI Minor bleeding, or bleeding that required unplanned medical or surgical treatment or unplanned laboratory evaluation even if it did not meet the criteria for TIMI major or minor bleeding. The Kaplan-Meier estimate reports the percentage of participants who experienced clinically significant bleeding within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Death From Any Cause, MI, Stroke, or UCR Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to the occurrence of any of the following clinical outcomes was recorded: death from any cause, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced death from any cause, MI, stroke, or UCR within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death or an MI Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to the occurrence of CV death or MI. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death or MI within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, UCR, or Urgent Hospitalization for Vascular Cause of Ischemic Nature (UH-VCIN) Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, UCR or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, UCR, or UH-VCIN within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause, or Experienced an MI, Stroke, or Any Revascularization Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to death from any cause or the first occurrence of any of the following clinical outcomes was recorded: MI, stroke, or any revascularization procedure . A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause, or experienced an MI, stroke, or any revascularization within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, Any Revascularization, or UH-VCIN Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, any revascularization, or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, any revascularization procedure, or UH-VCIN within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to CV death (if reported) was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced an MI Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of an MI was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced an MI within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced UCR Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of UCR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced UCR within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced a Stroke Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to first experience of a stroke was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced a stroke within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to death from any cause was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Had a UH-VCIN Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of an UH-VCIN was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had a UH-VCIN within 3 years from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Had Any Revascularization Performed Within 3 Years From Randomization</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time (in days) from study start to the first occurrence of a revascularization was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had any revascularization performed within 3 years from randomization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26449</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Ischemia</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Cerebrovascular Accident</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vorapaxar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorapaxar</intervention_name>
    <description>2.5-mg tablet daily for at least 1 year</description>
    <arm_group_label>Vorapaxar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching tablet daily for at least 1 year</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men and women at least 18 years old with evidence or a history of atherosclerosis involving
        the coronary, cerebral, or peripheral vascular systems by one or more of the following:

          -  history of myocardial infarction (heart attack)

          -  history of ischemic stroke (stroke due to a blocked artery)

          -  history of peripheral arterial disease

        Exclusion Criteria:

          -  history of intracranial hemorrhage or of central nervous system (CNS) surgery, tumor,
             or aneurysm

          -  any bleeding disorder or abnormality

          -  sustained severe hypertension or valvular heart disease

          -  current or recent platelet count &lt;100,000 mm^3

          -  planned or ongoing treatment with a blood thinning medication

          -  pregnancy

          -  any significant medical or physiological condition or abnormality that could put the
             subject at increased risk or limit the subject's ability to participate for the
             duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2007</study_first_submitted>
  <study_first_submitted_qc>September 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 18, 2014</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorapaxar</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=P04737&amp;kw=P04737&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Prior to planned study completion, the Data Safety Monitoring Board (DSMB) recommended discontinuation of study drug in all participants with a pre- or post-randomization history of stroke. A total of 4510 participants had study medication stopped, however these participants were included in the overall population for efficacy and safety analyses.</recruitment_details>
      <pre_assignment_details>The Intent to Treat (ITT) Population, defined as all enrolled participants who were randomly assigned to a treatment group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
        </group>
        <group group_id="P2">
          <title>Vorapaxar</title>
          <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13224"/>
                <participants group_id="P2" count="13225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="13166"/>
                <participants group_id="P2" count="13186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12932"/>
                <participants group_id="P2" count="12953"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
                <participants group_id="P2" count="272"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent to Treat (ITT) Population, defined as all enrolled participants who were randomly assigned to a treatment group.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
        </group>
        <group group_id="B2">
          <title>Vorapaxar</title>
          <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13224"/>
            <count group_id="B2" value="13225"/>
            <count group_id="B3" value="26449"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8273"/>
                    <measurement group_id="B2" value="8188"/>
                    <measurement group_id="B3" value="16461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-&lt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3445"/>
                    <measurement group_id="B2" value="3523"/>
                    <measurement group_id="B3" value="6968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1506"/>
                    <measurement group_id="B2" value="1514"/>
                    <measurement group_id="B3" value="3020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3172"/>
                    <measurement group_id="B2" value="3154"/>
                    <measurement group_id="B3" value="6326"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10052"/>
                    <measurement group_id="B2" value="10071"/>
                    <measurement group_id="B3" value="20123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, or Urgent Coronary Revascularization (UCR) Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A Clinical Endpoints Committee (CEC) reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intent to Treat (ITT) Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, or Urgent Coronary Revascularization (UCR) Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A Clinical Endpoints Committee (CEC) reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 3 years from randomization.</description>
          <population>Intent to Treat (ITT) Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4"/>
                    <measurement group_id="O2" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, or Stroke Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, or stroke. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, or stroke within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, or Stroke Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, or stroke. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, or stroke within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Met Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) Moderate or Severe Bleeding Criteria Within 3 Years From Randomization</title>
        <description>Adverse events were categorized as “bleeding events” if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the GUSTO cooperative group criteria as follows: Mild , Moderate or Severe and the grading was adjudicated by the CEC. The Kaplan-Meier estimate reports the percentage of participants who experienced GUSTO moderate or severe bleeding within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>As Treated Population, which included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Met Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) Moderate or Severe Bleeding Criteria Within 3 Years From Randomization</title>
          <description>Adverse events were categorized as “bleeding events” if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the GUSTO cooperative group criteria as follows: Mild , Moderate or Severe and the grading was adjudicated by the CEC. The Kaplan-Meier estimate reports the percentage of participants who experienced GUSTO moderate or severe bleeding within 3 years from randomization.</description>
          <population>As Treated Population, which included all participants who received at least 1 dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13166"/>
                <count group_id="O2" value="13186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Clinically Significant Bleeding Within 3 Years From Randomization</title>
        <description>Adverse events were categorized as “bleeding events” if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria as major, minor or other. “Clinically Significant Bleeding” was defined as the composite of TIMI Major bleeding, TIMI Minor bleeding, or bleeding that required unplanned medical or surgical treatment or unplanned laboratory evaluation even if it did not meet the criteria for TIMI major or minor bleeding. The Kaplan-Meier estimate reports the percentage of participants who experienced clinically significant bleeding within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>As Treated Population, which included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Clinically Significant Bleeding Within 3 Years From Randomization</title>
          <description>Adverse events were categorized as “bleeding events” if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria as major, minor or other. “Clinically Significant Bleeding” was defined as the composite of TIMI Major bleeding, TIMI Minor bleeding, or bleeding that required unplanned medical or surgical treatment or unplanned laboratory evaluation even if it did not meet the criteria for TIMI major or minor bleeding. The Kaplan-Meier estimate reports the percentage of participants who experienced clinically significant bleeding within 3 years from randomization.</description>
          <population>As Treated Population, which included all participants who received at least 1 dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13166"/>
                <count group_id="O2" value="13186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Death From Any Cause, MI, Stroke, or UCR Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the occurrence of any of the following clinical outcomes was recorded: death from any cause, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced death from any cause, MI, stroke, or UCR within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Death From Any Cause, MI, Stroke, or UCR Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the occurrence of any of the following clinical outcomes was recorded: death from any cause, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced death from any cause, MI, stroke, or UCR within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Perentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2"/>
                    <measurement group_id="O2" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death or an MI Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the occurrence of CV death or MI. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death or MI within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death or an MI Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the occurrence of CV death or MI. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death or MI within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, UCR, or Urgent Hospitalization for Vascular Cause of Ischemic Nature (UH-VCIN) Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, UCR or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, UCR, or UH-VCIN within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, UCR, or Urgent Hospitalization for Vascular Cause of Ischemic Nature (UH-VCIN) Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, UCR or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, UCR, or UH-VCIN within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause, or Experienced an MI, Stroke, or Any Revascularization Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to death from any cause or the first occurrence of any of the following clinical outcomes was recorded: MI, stroke, or any revascularization procedure . A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause, or experienced an MI, stroke, or any revascularization within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause, or Experienced an MI, Stroke, or Any Revascularization Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to death from any cause or the first occurrence of any of the following clinical outcomes was recorded: MI, stroke, or any revascularization procedure . A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause, or experienced an MI, stroke, or any revascularization within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6"/>
                    <measurement group_id="O2" value="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, Any Revascularization, or UH-VCIN Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, any revascularization, or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, any revascularization procedure, or UH-VCIN within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, Any Revascularization, or UH-VCIN Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, any revascularization, or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, any revascularization procedure, or UH-VCIN within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1"/>
                    <measurement group_id="O2" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to CV death (if reported) was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to CV death (if reported) was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced an MI Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of an MI was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced an MI within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced an MI Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of an MI was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced an MI within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced UCR Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of UCR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced UCR within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced UCR Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of UCR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced UCR within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced a Stroke Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to first experience of a stroke was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced a stroke within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced a Stroke Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to first experience of a stroke was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced a stroke within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.733</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to death from any cause was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to death from any cause was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.411</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Had a UH-VCIN Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of an UH-VCIN was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had a UH-VCIN within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Had a UH-VCIN Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of an UH-VCIN was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had a UH-VCIN within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Had Any Revascularization Performed Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of a revascularization was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had any revascularization performed within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Had Any Revascularization Performed Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of a revascularization was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had any revascularization performed within 3 years from randomization.</description>
          <population>ITT Population, defined as all participants who were randomly assigned to a treatment arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13224"/>
                <count group_id="O2" value="13225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, or UCR Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with coronary arterial disease (CAD) or peripheral arterial disease (PAD) and no history of a stroke or transient ischemic attack (TIA)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, or UCR Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with coronary arterial disease (CAD) or peripheral arterial disease (PAD) and no history of a stroke or transient ischemic attack (TIA)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, or Stroke Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, or stroke. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, or stroke within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, or Stroke Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, or stroke. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, or stroke within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Met GUSTO Moderate or Severe Bleeding Criteria Within 3 Years From Randomization</title>
        <description>Adverse events were categorized as “bleeding events” if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the GUSTO cooperative group criteria as follows: Mild , Moderate or Severe and the grading was adjudicated by the CEC. The Kaplan-Meier estimate reports the percentage of participants who experienced GUSTO moderate or severe bleeding within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Safety Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Met GUSTO Moderate or Severe Bleeding Criteria Within 3 Years From Randomization</title>
          <description>Adverse events were categorized as “bleeding events” if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the GUSTO cooperative group criteria as follows: Mild , Moderate or Severe and the grading was adjudicated by the CEC. The Kaplan-Meier estimate reports the percentage of participants who experienced GUSTO moderate or severe bleeding within 3 years from randomization.</description>
          <population>Intended Label Safety Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA who received at least 1 dose of study drug</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10049"/>
                <count group_id="O2" value="10059"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Clinically Significant Bleeding Within 3 Years From Randomization</title>
        <description>Adverse events were categorized as “bleeding events” if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the TIMI Study Group criteria as major, minor or other. “Clinically Significant Bleeding” was defined as the composite of TIMI Major bleeding, TIMI Minor bleeding, or bleeding that required unplanned medical or surgical treatment or unplanned laboratory evaluation even if it did not meet the criteria for TIMI major or minor bleeding. The Kaplan-Meier estimate reports the percentage of participants who experienced clinically significant bleeding within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Safety Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Clinically Significant Bleeding Within 3 Years From Randomization</title>
          <description>Adverse events were categorized as “bleeding events” if the intensity, frequency, or type of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the TIMI Study Group criteria as major, minor or other. “Clinically Significant Bleeding” was defined as the composite of TIMI Major bleeding, TIMI Minor bleeding, or bleeding that required unplanned medical or surgical treatment or unplanned laboratory evaluation even if it did not meet the criteria for TIMI major or minor bleeding. The Kaplan-Meier estimate reports the percentage of participants who experienced clinically significant bleeding within 3 years from randomization.</description>
          <population>Intended Label Safety Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA who received at least 1 dose of study drug</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10049"/>
                <count group_id="O2" value="10059"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Death From Any Cause, MI, Stroke, or UCR Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the occurrence of any of the following clinical outcomes was recorded: death from any cause, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced death from any cause, MI, stroke, or UCR within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Death From Any Cause, MI, Stroke, or UCR Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the occurrence of any of the following clinical outcomes was recorded: death from any cause, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced death from any cause, MI, stroke, or UCR within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death or an MI Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the occurrence of CV death or first occurrence of an MI. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death or MI within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death or an MI Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the occurrence of CV death or first occurrence of an MI. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death or MI within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, UCR, or UH-VCIN Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, UCR, or UH-VCIN . A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, UCR, or UH-VCIN within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, UCR, or UH-VCIN Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, UCR, or UH-VCIN . A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, UCR, or UH-VCIN within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause, or Experienced an MI, Stroke, or Any Revascularization Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to death from any cause or the first occurrence of any of the following clinical outcomes was recorded: MI, stroke, or any revascularization procedure . A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause, or experienced an MI, stroke, or any revascularization within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause, or Experienced an MI, Stroke, or Any Revascularization Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to death from any cause or the first occurrence of any of the following clinical outcomes was recorded: MI, stroke, or any revascularization procedure . A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause, or experienced an MI, stroke, or any revascularization within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, Any Revascularization, or UH-VCIN Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, any revascularization, or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, any revascularization procedure, or UH-VCIN within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death, MI, Stroke, Any Revascularization, or UH-VCIN Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, any revascularization, or UH-VCIN. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, any revascularization procedure, or UH-VCIN within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the CV death (if reported) was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced CV Death Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the CV death (if reported) was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced an MI Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of an MI was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced an MI within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced an MI Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of an MI was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced an MI within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced UCR Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of UCR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced UCR within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced UCR Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of UCR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced UCR within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced a Stroke Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to first experience of a stroke was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced a stroke within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Experienced a Stroke Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to first experience of a stroke was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced a stroke within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to death from any cause was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Died From Any Cause Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to death from any cause was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.249</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Had a UH-VCIN Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of a UH-VCIN was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had a UH-VCIN within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Had a UH-VCIN Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of a UH-VCIN was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had a UH-VCIN within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of the Percentage of Participants Who Had Any Revascularization Performed Within 3 Years From Randomization</title>
        <description>The time (in days) from study start to the first occurrence of any revascularization was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had any revascularization performed within 3 years from randomization.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar</title>
            <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Percentage of Participants Who Had Any Revascularization Performed Within 3 Years From Randomization</title>
          <description>The time (in days) from study start to the first occurrence of any revascularization was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who had any revascularization performed within 3 years from randomization.</description>
          <population>Intended Label Population: all enrolled participants with CAD or PAD and no history of a stroke or TIA</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10090"/>
                <count group_id="O2" value="10080"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6"/>
                    <measurement group_id="O2" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <method_desc>Hazard Ratio calculated with covariates for treatment and stratification factors</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>Hazard ratio calculated by dividing the Kaplan-Meier (KM) Estimate for vorapaxar by the KM Estimate for Placebo and correcting for covariates. A hazard ratio &lt;1 would indicate a lower hazard associated with vorapaxar relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 3 years</time_frame>
      <desc>Adverse events are reported using the As Treated Population, which included all participants who received at least 1 dose of study medication and are reported according to treatment received</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
        </group>
        <group group_id="E2">
          <title>Vorapaxar</title>
          <description>one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3419" subjects_at_risk="13166"/>
                <counts group_id="E2" subjects_affected="3514" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="13166"/>
                <counts group_id="E2" events="47" subjects_affected="45" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANAEMIA HAEMOLYTIC AUTOIMMUNE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANAEMIA OF CHRONIC DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>APLASIA PURE RED CELL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>AUTOIMMUNE THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC DIATHESIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPARIN-INDUCED THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>IDIOPATHIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MICROCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEPHROGENIC ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NORMOCHROMIC NORMOCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERNICIOUS ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPLENIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="13166"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>THROMBOTIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ADAMS-STOKES SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA SUPRAVENTRICULAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="118" subjects_affected="106" subjects_at_risk="13166"/>
                <counts group_id="E2" events="156" subjects_affected="137" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="13166"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="13166"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK FIRST DEGREE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BIFASCICULAR BLOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="13166"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK LEFT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK RIGHT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIAC ANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIAC ASTHMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="222" subjects_affected="174" subjects_at_risk="13166"/>
                <counts group_id="E2" events="245" subjects_affected="183" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="99" subjects_affected="82" subjects_at_risk="13166"/>
                <counts group_id="E2" events="121" subjects_affected="95" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIAC TAMPONADE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHRONOTROPIC INCOMPETENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CONDUCTION DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DRESSLER'S SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEART VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE HEART DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE PROLAPSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL RUPTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MYOPERICARDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NODAL ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERICARDIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULSELESS ELECTRICAL ACTIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="13166"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SINUS ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SINUS ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STRESS CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="13166"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TORSADE DE POINTES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ASYSTOLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VENTRICULAR DYSSYNCHRONY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="13166"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="49" subjects_affected="37" subjects_at_risk="13166"/>
                <counts group_id="E2" events="42" subjects_affected="37" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIOVENOUS MALFORMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ATRIAL SEPTAL DEFECT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EPIDERMOLYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ANGIODYSPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ANGIODYSPLASIA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ARTERIOVENOUS MALFORMATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ARTERIOVENOUS MALFORMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HIP DYSPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYDROCELE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PHIMOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PORPHYRIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PYLORIC STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VENTRICULAR SEPTAL DEFECT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE VESTIBULAR SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOACUSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENIERE'S DISEASE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUDDEN HEARING LOSS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="13166"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VESTIBULAR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADDISON'S DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ADRENAL MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>AUTOIMMUNE THYROIDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BASEDOW'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA OF MALIGNANCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERPARATHYROIDISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>AMAUROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLINDNESS UNILATERAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="13166"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CORNEAL OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETIC RETINOPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENDOCRINE OPHTHALMOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EYE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPHAEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LACRIMATION INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MACULAR DEGENERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MACULAR FIBROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MACULAR HOLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OCULAR HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OPTIC ISCHAEMIC NEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OPTIC NEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POSTERIOR CAPSULE OPACIFICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RETINAL ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RETINAL VEIN OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RETINAL VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ULCERATIVE KERATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VISUAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VITREOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ADHESIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABDOMINAL COMPARTMENT SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABDOMINAL MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="13166"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ACUTE ABDOMEN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANAL FISTULA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BARRETT'S OESOPHAGUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BUCCAL POLYP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COLITIS EROSIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COLONIC PSEUDO-OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="13166"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DENTAL NECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETIC GASTROPARESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIARRHOEA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM OESOPHAGEAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DUODENAL PERFORATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DUODENITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENTEROCELE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENTEROVESICAL FISTULA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EPIGASTRIC DISCOMFORT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EPIPLOIC APPENDAGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EROSIVE DUODENITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EROSIVE OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FAECES DISCOLOURED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FEMORAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FUNCTIONAL GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC VOLVULUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="13166"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRITIS ALCOHOLIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRITIS ATROPHIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRODUODENAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="42" subjects_affected="38" subjects_at_risk="13166"/>
                <counts group_id="E2" events="70" subjects_affected="62" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL NECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TELANGIECTASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="33" subjects_affected="31" subjects_at_risk="13166"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="13166"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="13166"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HERNIAL EVENTRATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ILEAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INFLAMMATORY BOWEL DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="13166"/>
                <counts group_id="E2" events="44" subjects_affected="42" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA STRANGULATED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTESTINAL MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTESTINAL POLYP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTESTINAL STRANGULATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>JEJUNAL PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUMBAR HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MALABSORPTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MECHANICAL ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" events="49" subjects_affected="44" subjects_at_risk="13166"/>
                <counts group_id="E2" events="76" subjects_affected="69" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MESENTERIC ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MESENTERIC ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MESENTERIC VASCULAR INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MOUTH CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ACHALASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL SPASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PANCREATIC CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PANCREATIC DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="13166"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="13166"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PANCREATITIS RELAPSING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PAPILLA OF VATER STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PAROTID GLAND ENLARGEMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PHARYNGOESOPHAGEAL DIVERTICULUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POLYP COLORECTAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROCTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROCTITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROCTITIS ULCERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="41" subjects_affected="37" subjects_at_risk="13166"/>
                <counts group_id="E2" events="59" subjects_affected="53" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RECTAL PROLAPSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RECTAL ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND CALCULUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="13166"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPIGELIAN HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPLENIC ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>THROMBOSIS MESENTERIC VESSEL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TONGUE HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TONGUE OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="13166"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VARICES OESOPHAGEAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="13166"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE BLEEDING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="13166"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CYST RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEVICE BREAKAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEVICE FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEVICE LEAD DAMAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEVICE OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DISCOMFORT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DRUG INTERACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EXERCISE TOLERANCE DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GRAVITATIONAL OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERTROPHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOTHERMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ILL-DEFINED DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE EROSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INFLAMMATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NODULE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="548" subjects_affected="458" subjects_at_risk="13166"/>
                <counts group_id="E2" events="519" subjects_affected="443" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERFORATED ULCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POLYP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POLYSEROSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="13166"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SYSTEMIC INFLAMMATORY RESPONSE SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BILIARY DILATATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BILIARY DYSKINESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="13166"/>
                <counts group_id="E2" events="32" subjects_affected="31" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="13166"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="13166"/>
                <counts group_id="E2" events="43" subjects_affected="42" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHOLESTASIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GALLBLADDER DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GALLBLADDER POLYP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATIC MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATITIS TOXIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATORENAL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATOTOXICITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC HEPATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY TO ARTHROPOD STING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC SHOCK</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FOOD ALLERGY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOGAMMAGLOBULINAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABSCESS INTESTINAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ABSCESS ORAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>APPENDICEAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="13166"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT SITE ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT SITE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTHRITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ASPERGILLOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BACTERIAL PROSTATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BILIARY SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLASTOCYSTIS INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BORRELIA INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="13166"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRONCHITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="13166"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CAMPYLOBACTER GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CAMPYLOBACTER INTESTINAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIAC INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="41" subjects_affected="38" subjects_at_risk="13166"/>
                <counts group_id="E2" events="45" subjects_affected="42" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CELLULITIS OF MALE EXTERNAL GENITAL ORGAN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CENTRAL NERVOUS SYSTEM INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHRONIC SINUSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COCCIDIOIDOMYCOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DENGUE FEVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED SEPSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETIC GANGRENE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DISSEMINATED TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="13166"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DYSENTERY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ECZEMA INFECTED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EMPYEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS HERPES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENDOPHTHALMITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENTERITIS INFECTIOUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENTEROBACTER INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS INFECTIOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EPIDEMIC NEPHROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EPIGLOTTITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="13166"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EYE ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FUNGAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="39" subjects_affected="37" subjects_at_risk="13166"/>
                <counts group_id="E2" events="37" subjects_affected="36" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS ESCHERICHIA COLI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS NOROVIRUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GINGIVAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GRAFT INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GROIN ABSCESS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GROIN INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>H1N1 INFLUENZA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMATOMA INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HELICOBACTER INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATITIS B</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATITIS C</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HERPES SIMPLEX</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HISTOPLASMOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HIV INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INCISION SITE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INFECTED BITES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INFECTED DERMAL CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INFECTED SKIN ULCER</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INFECTIOUS PERITONITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INFECTIOUS PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INFUSION SITE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LABYRINTHITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LIVER ABSCESS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="13166"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LYME DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LYMPHANGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MASTOIDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MEDIASTINITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENINGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENINGITIS ASEPTIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENINGITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENINGITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MYCOBACTERIUM AVIUM COMPLEX INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NECROTISING FASCIITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ONYCHOMYCOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ORAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="13166"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS CHRONIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OTITIS EXTERNA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA CHRONIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PAROTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERICARDITIS INFECTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERIDIVERTICULAR ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERINEAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERINEPHRIC ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERIORBITAL CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERITONSILLAR ABSCESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PILONIDAL CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS JIROVECI PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="205" subjects_affected="186" subjects_at_risk="13166"/>
                <counts group_id="E2" events="185" subjects_affected="167" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ESCHERICHIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PNEUMONIA FUNGAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PNEUMONIA MYCOPLASMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PNEUMONIA VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ABSCESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="13166"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PSEUDOMEMBRANOUS COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PSOAS ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY SEPSIS</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="13166"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="13166"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RECTAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SALMONELLA SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SALMONELLOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SCROTAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="13166"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SEPTIC NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="13166"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SERRATIA INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SIALOADENITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SINUSITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUPERINFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SYPHILIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SYSTEMIC CANDIDA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TYPHUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="53" subjects_affected="50" subjects_at_risk="13166"/>
                <counts group_id="E2" events="67" subjects_affected="62" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION PSEUDOMONAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="13166"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VAGINAL INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VESTIBULAR NEURONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VIRAL LABYRINTHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VIRAL MYOCARDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WOUND ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION PSEUDOMONAS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WOUND SEPSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ACCIDENT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ACETABULUM FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANAEMIA POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="13166"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTERIAL INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTHROPOD STING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRAIN CONTUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BURNS THIRD DEGREE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARBON MONOXIDE POISONING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIAC FUNCTION DISTURBANCE POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARTILAGE INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHEMICAL EYE INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHEST INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CONFUSION POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CYSTITIS RADIATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EAR INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ELECTRIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EXCORIATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EXTRADURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FACE INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="13166"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FEBRILE NONHAEMOLYTIC TRANSFUSION REACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="13166"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FLAIL CHEST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FOREARM FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FOREIGN BODY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STOMA COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GUN SHOT WOUND</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEAT EXHAUSTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEAT STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="13166"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INCISION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INCISION SITE PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>JAW FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LIMB TRAUMATIC AMPUTATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MULTIPLE DRUG OVERDOSE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MULTIPLE FRACTURES</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MULTIPLE INJURIES</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MUSCLE RUPTURE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MUSCLE STRAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NERVE INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OPEN FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OPEN WOUND</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OPERATIVE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="13166"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PATELLA FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERIPROSTHETIC FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POISONING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL DISCHARGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="13166"/>
                <counts group_id="E2" events="40" subjects_affected="39" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ADHESION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE FEVER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ILEUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE THORACIC PROCEDURE COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POSTPERICARDIOTOMY SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PUBIS FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RADIATION ASSOCIATED PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RADIATION INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RADIATION OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="13166"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SCAPULA FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SEROMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SKIN FLAP NECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SNAKE BITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPLENIC RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STAB WOUND</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STERNAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STRUCK BY LIGHTNING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="13166"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRANSFUSION-RELATED ACUTE LUNG INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRAUMATIC ARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRAUMATIC INTRACRANIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRAUMATIC LIVER INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ULNA FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VACCINATION COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VASCULAR INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WOUND EVISCERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WOUND HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WOUND NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLOOD TRIGLYCERIDES INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARDIAC STRESS TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM TEST POSITIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EXERCISE ELECTROCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EXERCISE TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMATOCRIT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HIV TEST POSITIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OCCULT BLOOD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OCCULT BLOOD POSITIVE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT ABNORMAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PRECANCEROUS CELLS PRESENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROTEIN URINE PRESENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY FUNCTION TEST DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RED BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RED BLOOD CELLS URINE POSITIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="34" subjects_affected="33" subjects_at_risk="13166"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="13166"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="13166"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETIC COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMOSIDEROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="13166"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERVOLAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="13166"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOPHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>IRON METABOLISM DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TYPE 1 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VITAMIN B12 DEFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="13166"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTHROFIBROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTHROPATHY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="13166"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BONE CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BONE FISTULA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHONDROMALACIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COMPARTMENT SYNDROME</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DUPUYTREN'S CONTRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EXOSTOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FIBROMYALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FOOT DEFORMITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FRACTURE NONUNION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GOUTY ARTHRITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GROIN PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMARTHROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="13166"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LIGAMENT LAXITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENISCAL DEGENERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MONARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MUSCLE ATROPHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MUSCLE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="13166"/>
                <counts group_id="E2" events="44" subjects_affected="41" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="13166"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MYOFASCIAL PAIN SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MYOSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEUROPATHIC ARTHROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OSTEITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="89" subjects_affected="84" subjects_at_risk="13166"/>
                <counts group_id="E2" events="76" subjects_affected="71" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OSTEOCHONDROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OSTEOLYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PAIN IN JAW</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERIARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POLYARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POLYMYALGIA RHEUMATICA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PSEUDARTHROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SCOLIOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="13166"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPINAL DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPONDYLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPONDYLOLISTHESIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SYMPATHETIC POSTERIOR CERVICAL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SYNOVIAL CYST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TENDON DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TENDON NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TENDONITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TENOSYNOVITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRIGGER FINGER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VERTEBRAL WEDGING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE LEUKAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ACUTE LYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ADENOMA BENIGN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ADRENAL ADENOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ADRENAL NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANAL NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANOGENITAL WARTS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ASTROCYTOMA MALIGNANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ATYPICAL FIBROXANTHOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="13166"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BENIGN CARDIAC NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BENIGN LUNG NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BENIGN NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BENIGN NEOPLASM OF BLADDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BENIGN NEOPLASM OF SKIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BENIGN NEOPLASM OF TESTIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BENIGN NEOPLASM OF THYROID GLAND</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BENIGN RENAL NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BENIGN SALIVARY GLAND NEOPLASM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BILE DUCT CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BILIARY CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BILIARY NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="13166"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER RECURRENT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER PAPILLOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BONE NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRAIN NEOPLASM</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="13166"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BREAST CANCER IN SITU</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BREAST CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BREAST CANCER RECURRENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BREAST NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRONCHIAL CARCINOMA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRONCHIOLOALVEOLAR CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARCINOID TUMOUR OF THE DUODENUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARCINOMA IN SITU</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CERVIX CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHLOROMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHOLESTEATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHONDROMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHONDROSARCOMA METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHOROID MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHRONIC LYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHRONIC MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="13166"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COLON CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COLON CANCER STAGE 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COLON NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COLORECTAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CONNECTIVE TISSUE NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ESSENTIAL THROMBOCYTHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FIBROUS HISTIOCYTOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC ADENOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER STAGE III</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL CARCINOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TRACT ADENOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GLIOBLASTOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GLIOBLASTOMA MULTIFORME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMANGIOMA OF SPLEEN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATIC ANGIOSARCOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATIC CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT RECURRENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HODGKIN'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOPHARYNGEAL CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOPHARYNGEAL CANCER STAGE III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INFECTED NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTESTINAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTRADUCTAL PAPILLOMA OF BREAST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>KERATOACANTHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARGE CELL CARCINOMA OF THE RESPIRATORY TRACT STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARGE CELL LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARGE GRANULAR LYMPHOCYTOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARYNGEAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARYNGEAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARYNGEAL CANCER STAGE 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARYNGEAL NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LEIOMYOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LEIOMYOSARCOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LEIOMYOSARCOMA METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LEUKAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LIP AND/OR ORAL CAVITY CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LIP NEOPLASM MALIGNANT STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LIPOMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LIPOSARCOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA RECURRENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="13166"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="13166"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LYMPHANGIOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTIC LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MALIGNANT FIBROUS HISTIOCYTOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MALIGNANT GLIOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MALIGNANT NEOPLASM OF EYE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MALIGNANT PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MANTLE CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MELANOMA RECURRENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENINGIOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENINGIOMA BENIGN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MESOTHELIOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MESOTHELIOMA MALIGNANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTASES TO BONE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTASES TO CENTRAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTASES TO LIVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTASES TO LUNG</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTASES TO PERITONEUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTATIC BRONCHIAL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTATIC CARCINOMA OF THE BLADDER</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTATIC GASTRIC CANCER</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTATIC LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTATIC MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTATIC NEOPLASM</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTATIC SALIVARY GLAND CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METASTATIC SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MONOCLONAL GAMMOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MULTIPLE MYELOMA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGEAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGEAL CANCER RECURRENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEOPLASM PROSTATE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEUROENDOCRINE CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEUROMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA RECURRENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA STAGE II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER STAGE IIIB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER STAGE IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ORAL CAVITY CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ORAL PAPILLOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OSTEOCHONDROMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OVARIAN ADENOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OVARIAN EPITHELIAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OVARIAN NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PAPILLOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PARAPROTEINAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PARATHYROID TUMOUR BENIGN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PENIS CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PENIS CARCINOMA STAGE II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PITUITARY TUMOUR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PITUITARY TUMOUR BENIGN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PLEURAL MESOTHELIOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POLYCYTHAEMIA VERA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="54" subjects_affected="54" subjects_at_risk="13166"/>
                <counts group_id="E2" events="39" subjects_affected="38" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER RECURRENT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER STAGE I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER STAGE II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER STAGE IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROSTATIC ADENOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RECTAL ADENOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RECTOSIGMOID CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL CANCER STAGE III</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA RECURRENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL ONCOCYTOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RHABDOMYOSARCOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND NEOPLASM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC KERATOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SKIN CANCER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SKIN NEOPLASM BLEEDING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SMALL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINE CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINE CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF THE CERVIX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>T-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>THYMOMA MALIGNANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>THYROID ADENOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>THYROID CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TONSIL CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TUMOUR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URETERAL NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URETERIC CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UTERINE CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UTERINE NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VULVAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>AMYOTROPHIC LATERAL SCLEROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ATAXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>AUTONOMIC NERVOUS SYSTEM IMBALANCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BASAL GANGLIA HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRAIN OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRAIN STEM HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CAUDA EQUINA SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CEREBRAL AMYLOID ANGIOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CEREBRAL CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CERVICAL MYELOPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CNS VENTRICULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COGNITIVE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COMPLEX PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COMPLEX REGIONAL PAIN SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COMPLICATED MIGRAINE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="13166"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CRANIAL NERVE PARALYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CUBITAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEMENTIA ALZHEIMER'S TYPE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEMYELINATING POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETIC COMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETIC NEUROPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIZZINESS EXERTIONAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIZZINESS POSTURAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DYSAESTHESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENCEPHALOMYELITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="13166"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FACIAL PARESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GUILLAIN-BARRE SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" events="43" subjects_affected="42" subjects_at_risk="13166"/>
                <counts group_id="E2" events="75" subjects_affected="75" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC TRANSFORMATION STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEMIANOPIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYDROCEPHALUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIC COMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOXIC-ISCHAEMIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>IIIRD NERVE PARALYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTERCOSTAL NEURALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL ANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTRAVENTRICULAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LEUKOENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LEWIS-SUMNER SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUMBAR RADICULOPATHY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENTAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MONOPLEGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MYELOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MYOCLONUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NERVE COMPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NERVE ROOT COMPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEURITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEUROLOGICAL SYMPTOM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NORMAL PRESSURE HYDROCEPHALUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PARAPARESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PARAPLEGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PARKINSON'S DISEASE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PARKINSONISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PARTIAL SEIZURES WITH SECONDARY GENERALISATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERIPHERAL NERVE LESION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="13166"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PUTAMEN HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>QUADRIPARESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RADICULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RADICULOPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SEDATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPINAL CLAUDICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STATUS EPILEPTICUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="65" subjects_affected="60" subjects_at_risk="13166"/>
                <counts group_id="E2" events="87" subjects_affected="81" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SYRINGOMYELIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TENSION HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>THORACIC OUTLET SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRANSIENT GLOBAL AMNESIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRIGEMINAL NEURALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ULNAR NEURITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UPPER MOTOR NEURONE LESION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VASCULAR DEMENTIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VASCULAR PARKINSONISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VERTEBRAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VOCAL CORD PARALYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WERNICKE'S ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION MISSED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ADJUSTMENT DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ALCOHOL ABUSE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ALCOHOLISM</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13166"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANXIETY DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BIPOLAR I DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CONVERSION DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEPRESSED MOOD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="13166"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MANIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENTAL DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POLYDIPSIA PSYCHOGENIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POST STROKE DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SCHIZOPHRENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SOMATOFORM DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STRESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUBSTANCE ABUSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TRANSIENT PSYCHOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PRERENAL FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>AZOTAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER NECK OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER NECK SCLEROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER OUTLET OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER PROLAPSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER SPASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLADDER STENOSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CALCULUS BLADDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CALCULUS URETHRAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CYSTITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CYSTITIS NONINFECTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETIC NEPHROPATHY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GLOMERULONEPHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GLOMERULONEPHRITIS MEMBRANOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="42" subjects_affected="38" subjects_at_risk="13166"/>
                <counts group_id="E2" events="72" subjects_affected="66" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE URINARY TRACT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYDROURETER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>KIDNEY FIBROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MICTURITION URGENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="33" subjects_affected="28" subjects_at_risk="13166"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEPHROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NEPHROTIC SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE UROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PELVI-URETERIC OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POLYURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="42" subjects_affected="40" subjects_at_risk="13166"/>
                <counts group_id="E2" events="34" subjects_affected="33" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="61" subjects_affected="54" subjects_at_risk="13166"/>
                <counts group_id="E2" events="44" subjects_affected="43" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="13166"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL INFARCT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RENAL TUBULAR NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STAG HORN CALCULUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STRESS URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TUBULOINTERSTITIAL NEPHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URETERIC RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URETERIC STENOSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URETHRAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URETHRAL STENOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URINARY BLADDER POLYP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URINARY TRACT DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VESICOURETERIC REFLUX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BALANITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="13166"/>
                <counts group_id="E2" events="36" subjects_affected="35" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BREAST ENLARGEMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL HYPERPLASIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EPIDIDYMITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ERECTILE DYSFUNCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FIBROCYSTIC BREAST DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GENITAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GENITAL TRACT INFLAMMATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENOMETRORRHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MENSTRUAL DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ORCHITIS NONINFECTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PELVIC HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PELVIC PROLAPSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POSTMENOPAUSAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROSTATIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROSTATISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROSTATITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PROSTATOMEGALY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RECTOCELE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPERMATOCELE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TESTICULAR OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UTERINE CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UTERINE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UTERINE PROLAPSE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>UTEROVAGINAL PROLAPSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VAGINAL LACERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VAGINAL PROLAPSE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VAGINAL ULCERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="13166"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ADENOIDAL DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>APNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ASPHYXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRAIN HYPOXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRONCHIAL HYPERREACTIVITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="100" subjects_affected="75" subjects_at_risk="13166"/>
                <counts group_id="E2" events="112" subjects_affected="79" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIAPHRAGMATIC PARALYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="13166"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DYSPNOEA PAROXYSMAL NOCTURNAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EMPHYSEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EOSINOPHILIC PNEUMONIA ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="13166"/>
                <counts group_id="E2" events="30" subjects_affected="29" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="13166"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYDROTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERVENTILATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOVENTILATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>IDIOPATHIC PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARYNGEAL MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LARYNGEAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG CONSOLIDATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NASAL POLYPS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NASAL SEPTUM DEVIATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NASAL SEPTUM DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>NASAL TURBINATE HYPERTROPHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE AIRWAYS DISORDER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="13166"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="13166"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY CALCIFICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="45" subjects_affected="45" subjects_at_risk="13166"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ACIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="13166"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SINUS POLYP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TONSILLAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VOCAL CORD ATROPHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VOCAL CORD POLYP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIODERMATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DERMATITIS ALLERGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DERMATITIS EXFOLIATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DERMATOMYOSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETIC DERMOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DIABETIC ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DRY GANGRENE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOCLASTIC VASCULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PEMPHIGOID</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PEMPHIGUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PETECHIAE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PURPURA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SCAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SEGMENTED HYALINISING VASCULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SKIN HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SKIN NECROSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>STASIS DERMATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>SOCIAL PROBLEM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL OPERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FINGER AMPUTATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>GASTRIC BANDING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HIP ARTHROPLASTY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA REPAIR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POLYPECTOMY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SPINAL DECOMPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SURGERY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ACCELERATED HYPERTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANEURYSM RUPTURED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ANGIODYSPLASIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="13166"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM RUPTURE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>AORTIC DILATATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13166"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTERIAL DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTERIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTERIAL RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>BLEEDING VARICOSE VEIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="13166"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ESSENTIAL HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>EXTREMITY NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="13166"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMODYNAMIC INSTABILITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="13166"/>
                <counts group_id="E2" events="40" subjects_affected="36" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="13166"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" events="35" subjects_affected="31" subjects_at_risk="13166"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE EMERGENCY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13166"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOPERFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="13166"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LABILE BLOOD PRESSURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LYMPHATIC FISTULA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LYMPHOCELE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>LYMPHOEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>MALIGNANT HYPERTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="13166"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PERIPHERAL EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>POOR PERIPHERAL CIRCULATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>RAYNAUD'S PHENOMENON</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>TEMPORAL ARTERITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VENOUS INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13166"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13186"/>
              </event>
              <event>
                <sub_title>WEGENER'S GRANULOMATOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2280" subjects_at_risk="13166"/>
                <counts group_id="E2" subjects_affected="2541" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="785" subjects_affected="687" subjects_at_risk="13166"/>
                <counts group_id="E2" events="789" subjects_affected="672" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="781" subjects_affected="704" subjects_at_risk="13166"/>
                <counts group_id="E2" events="746" subjects_affected="662" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="513" subjects_affected="401" subjects_at_risk="13166"/>
                <counts group_id="E2" events="1044" subjects_affected="807" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="789" subjects_affected="736" subjects_at_risk="13166"/>
                <counts group_id="E2" events="761" subjects_affected="712" subjects_at_risk="13186"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigators agreed not to publish or publicly present any interim results of the study without the prior written consent of the sponsor. The investigator further agreed to provide to the sponsor review copies of abstracts or manuscripts for publication 45 days prior to submission.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Prior to the completion of the study, based on a communication from the Data and Safety Monitoring Board, all participants who had experienced a stroke either before or during the study had study drug discontinued.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

